You are here

Home » Content

Evaluating Xenobiotic Metabolizing Enzymes, Cell Proliferation and Apoptosis Markers in Epithelial Ovarian Cancer patients.

Journal Name:

  • Indian Journal of Basic & Applied Medical Research

Publication Year:

  • 2013

Key Words:

Author NameUniversity of Author
Abstract (2. Language): 
Introduction: Adequate screening methods are not available for early stage ovarian cancer detection. We hypothesised that correlating the levels of phase I and phase II biotransformation enzymes involved in estrogen metabolism and correlating it with cell proliferation and apoptosis evasion would provide key hallmark traits for ovarian malignancy. The aim of the study was to evaluate the expression levels of phase I (cytochrome P450 total and the CYP isoforms CYP1A1, CYP1A2 and CYP2B) and phase II (GST and QR) xenobioticmetabolizing enzymes, as well as expression of markers reflecting cell proliferation (PCNA and cyclin D1) and apoptosis (Bcl-2 and Bax) in patients with epithelial ovarian cancer. Material & Methods: Hundred and fifteen ovarian tumor patients were chosen for the study. Out of 115 ovarian tissues of patients, 18 were histologically non-malignant and rest were malignant with grade III epithelial ovarian tumors. Results : The results of the present study demonstrated that the increase in phase I enzymes in ovarian tumour tissues were not compensated by a corresponding increase in phase II enzymes, indicating insufficient detoxification in the face of increased carcinogenic activation. Conclusion: The present study results provided evidence that an imbalance in phase I and phase II xenobioticmetabolizing enzymes, coupled with an imbalance in cell proliferation and apoptosis, are important contributors for the development of epithelial ovarian cancer.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon 810-822.pdf.pdf
  • 8
810-822
  • English

REFERENCES

References: 

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 vl.2,
Cancer incidence and mortality worldwide: IARC Cancer Base No. 10 (Internet).
2. Boyle P, Levin B. World Cancer Report 2008, IARC, Lyon: International Agency for
Research on Cancer. 2008; pp. 424-436.
3. Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and
current hypotheses. Cancer Epidemiol Biomarkers Prev .2005; 14: 98-107.
4. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol
Pathol .2008; 27: 161-174.
5. Sueblinvong T, Carney ME. Current understanding of risk factors for ovarian cancer.
Curr Treat Options Oncol .2009; 10: 67-81.
6. Nossov V, Amneus M, Su F, Lang J, Janco JM, Reddy ST, Farias-Eisner R. The early
detection of ovarian cancer: from traditional methods to proteomics. Can we really do
better than serum CA-125? Am J Obstet Gynecol . 2008; 199: 215-223.
Tumour Control
420 bp
415 bp Bax
293 bp Bcl 2
GAPDH
mRNA expression (%)
0
50
100
150
200
250
Bax Bcl-2
*
*
Tumour Control
Bax
Bcl 2
β-actin
23 kDa
26 kDa
43 kDa
0
50
100
150
200
250
300
Protein expression (%)
*
*
Bax Bcl-2
Indian Journal of Basic & Applied Medical Research; September 2013: Issue-8, Vol.-2, P. 810-822
820
www.ijbamr.com
7. Walsh CS, Karlan BY. Molecular signatures of ovarian cancer: from detection to
prognosis. Mol Diagn Ther .2010; 14: 13-22.
8. Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and
cancer. Oncogene .2006; 25: 1679-1691.
9. Ho SM. Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol
.2003; 1: 73.
10. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med.
2006; 354: 270-282.
11. McFadyen MC, Cruickshank ME, Miller ID, McLeod HL, Melvin WT, Haites NE,
Parkin D, Murray GI. Cytochrome P450 CYP1B1 over-expression in primary and
metastatic ovarian cancer. Br J Cancer. 2001; 85: 242-246.
12. Downie D, McFadyen MC, Rooney PH, Cruickshank ME, Parkin DE, Miller ID,
Telfer C, Melvin WT, Murray GI. Profiling cytochrome P450 expression in ovarian
cancer: identification of prognostic markers. Clin Cancer Res. 2005; 11: 7369-7375.
13. Ansell PJ, Espinosa-Nicholas C, Curran EM, Judy BM, Philips BJ, Hannink M,
Lubahn DB. In vitro and in vivo regulation of antioxidant response element-dependent
gene expression by estrogens. Endocrinology .2004; 145: 311-317.
14. Balch C, Huang TH, Brown R, Nephew KP. The epigenetics of ovarian cancer drug
resistance and resensitization. Am J Obstet Gynecol .2004; 191: 1552-1572.
15. Wu GQ, Xie D, Yang GF, Liao YJ, Mai SJ, Deng HX, Sze J, Guan XY, Zeng YX, Lin
MC, Kung HF. Cell cycle-related kinase supports ovarian carcinoma cell proliferation
via regulation of cyclin D1 and is a predictor of outcome in patients with ovarian
carcinoma. Int J Cancer .2009; 125: 2631-2642.
16. Wang S, Ma XY, Xia Y, Zhang LH. Expressions of Ki67, PCNA and mitotic index in
ovarian epithelial tumors. Sichuan Da Xue Xue Bao Yi Xue Ban .2010; 41: 575-580.
17. Bilyk OO, Pande NT, Buchynska LG. Analysis of p53, p16(INK4a), pRb and Cyclin
D1 expression and human papillomavirus in primary ovarian serous carcinomas. Exp
Oncol .2011; 33: 150-156.
18. Chaudhry P, Srinivasan R, Patel FD. Expression of the major fas family and Bcl-2
family of proteins in epithelial ovarian cancer (EOC) and their correlation to
chemotherapeutic response and outcome. Oncol Res .2010; 18: 549-559.
19. Spillman MA, Manning NG, Dye WW, Sartorius CA, Post MD, Harrell JC, Jacobsen
BM, Horwitz KB. Tissue-specific pathways for estrogen regulation of ovarian cancer
growth and metastasis. Cancer Res. 2010; 70: 927-936.
20. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Ström
A, Treuter E, Warner M, Gustafsson JA. Estrogen receptors: how do they signal and
what are their targets. Physiol Rev. 2007; 87: 905-931.
21. Ames BN, Durston WE, Yamasaki E, Lee FD. Carcinogens are mutagens: a simple test
system combining liver homogenates for activation and bacteria for detection. Proc
Natl Acad Sci .1973; 70: 2281-2285.
Indian Journal of Basic & Applied Medical Research; September 2013: Issue-8, Vol.-2, P. 810-822
821
www.ijbamr.com
22. Omura T, Sato R. The carbon monoxide binding pigment of liver. J Biol Chem. 1964;
239: 2370-2378.
23. Burke MD, Thompson S, Elcombe CR, Halpert J, Haparata T, Mayer RT. Ethoxypentoxy-
and benzyloxy phenoxazones and homologues: a series of substrates to
distinguish between different induced cytochromes P450. Biochem Pharmacol .1985;
34: 3337-3345.
24. Habig WH, Pabst M, Jakoby WB. Glutathione S-transferases, the first enzymatic step
in mercapturic acid formation. J Biol Chem .1974; 249: 130-139.
25. Ernster L. DT-diaphorase. In: Estabrook RW, Pullman ME. (eds). Methods Enzymol,
Academic Press, New York. 1967; 10: 309-317.
26. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin
phenol reagent. J Biol Chem .1951; 193: 265-275.
27. Legrand-Poels S, Schoonbrodt S, Piette J. Regulation of interleukin-6 gene expression
by pro-inflammatory cytokines in a colon cancer cell line. Biochem J. 2000; 349:765–
773.
28. Nagini S, Vidjaya Letchoumy P, Thangavelu A, Ramachandran C R. Of humans and
hamsters: A comparative evaluation of carcinogen activation, DNA damage, cell
proliferation, apoptosis, invasion, and angiogenesis in oral cancer patients and hamster
buccal pouch carcinomas. Oral Oncol .2009; 45:e31–e37.
29. Boverhof DR, Burgoon LD, Williams KJ, Zacharewski TR. Inhibition of estrogenmediated
uterine gene expression responses by dioxin. Mol Pharmacol .2008; 73: 82-
93.
30. Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev. 2000; 21: 40-54.
31. Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of
estrogens and its regulation in human. Cancer Lett .2005; 227: 115-124.
32. Saini S, Hirata H, Majid S, Dahiya R. Functional significance of cytochrome P450 1B1
in endometrial carcinogenesis. Cancer Res .2009; 69: 7038-7045.
33. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF. Cytochrome P450 1B1
(CYP1B1) pharmacogenetics: association of polymorphisms with functional
differences in estrogen hydroxylation activity. Cancer Res. 2000; 60: 3440–3444.
34. Holt SK, Rossing MA, Malone KE, Schwartz SM, Weiss NS, Chen C. Ovarian cancer
risk and polymorphisms involved in estrogen catabolism. Cancer Epidemiol
Biomarkers Prev. 2007; 16: 481-489.
35. Caslini C, Capo-chichi CD, Roland IH, Nicolas E, Yeung AT, Xu XX. Histone
modifications silence the GATA transcription factor genes in ovarian cancer.
Oncogene .2006; 25: 5446-5461.
36. Kenny FS, Hui R, Musgrove EA, Gee JM, Blamey RW, Nicholson RI, Sutherland RL,
Robertson JF. Overexpression of cyclin D1 messenger RNA predicts for poor
prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res .1999; 5: 2069-
2076.
Indian Journal of Basic & Applied Medical Research; September 2013: Issue-8, Vol.-2, P. 810-822
822
www.ijbamr.com
37. Kong F, Tong R, Jia L, Wei W, Miao X, Zhao X, Sun W, Yang G, Zhao C. OVCA1
inhibits the proliferation of epithelial ovarian cancer cells by decreasing cyclin D1 and
increasing p16. Mol Cell Biochem .2011; 354: 199-205.
38. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia
S, Liu CG, Alder H, Calin GA, Ménard S, Croce CM. MicroRNA signatures in human
ovarian cancer. Cancer Res .2007; 67: 8699-8707.
39. Akman BH, Can T, Erson-Bensan AE. Estrogen-induced upregulation and 3'-UTR
shortening of CDC6. Nucleic Acids Res. 2012; 40(21):10679-88.
40. Plotkin JB, Nowak MA. The different effects of apoptosis and DNA repair on
tumorigenesis. J Theor Biol. 2002; 214: 453-467.
41. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profiling
of estrogen up- and down-regulated gene expression in human breast cancer cells:
insights into gene networks and pathways underlying estrogenic control of proliferation
and cell phenotype. Endocrinology .2003; 144: 562-574.
42. Anderson NS, Bermudez Y, Badgwell D, Chen R, Nicosia SV, Bast RC Jr, Kruk PA.
Urinary levels of Bcl-2 are elevated in ovarian cancer patients. Gynecol Oncol. 2009;
112: 60-67.
43. Camlica H, Duranyildiz D, Tas F, Yasasever V. Statistical interpretation of CA125 and
Bcl-2 in serum of patients with late stage ovarian cancer. Am J Clin Oncol .2008; 31:
85-88.
44. Perillo B, Sasso A, Abbondanza C, Palumbo G. 17beta-estradiol inhibits apoptosis in
MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present
in the coding sequence. Mol Cell Biol .2000; 20: 890-901.
45. Pratt MA, White D, Kushwaha N, Tibbo E, Niu MY. Cytoplasmic mutant p53
increases Bcl-2 expression in estrogen receptor-positive breast cancer cells. Apoptosis
.2007; 12: 657-669.
46. Safe S, Kim K. Non-classical genomic estrogen receptor (ER)/specificity protein and
ER/activating protein-1 signaling pathways. J Mol Endocrinol .2008; 41: 263-275.

Thank you for copying data from http://www.arastirmax.com